Cardiorenal Syndrome
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 80 years old males and females; 2. Symptoms meeting the diagnostic criteria for CHF plus a history of CHF>=3 months or clinical symptoms of heart failure>=months; 3. NYHA cardiac function classification II through IV (hemodynamically stable); 4. Serum NT-proBNP >=450 pg/ml; 5. Any other reason leading to eGFR decrease (=3 months; 6. Voluntary participation in this study and understanding and signing of informed consent.
Exclusion criteria
Exclusion criteria: 1. Simultaneous merger of primary diseases such as liver function, blood system, and endocrine system, tumor patients, severe neuroendocrine system diseases and psychotic patients; 2. Patients with valvular heart disease with left ventricular outflow tract obstruction, myocarditis, hypertrophic cardiomyopathy, restrictive cardiomyopathy, large aneurysm, arterial dissection, congenital heart disease, and unobvious hemodynamic changes; 3. pregnant or preparing pregnant and lactating women; 4. allergic persons, or those known to be allergic to treatment drugs; 5. Participate in other drug clinical investigators within 1 month; 6. used any other Chinese patent medicine that could impair cardiorenal functions for previous 3 months; 7. According to the investigator's judgment, the patient cannot complete this study or cannot comply with the requirements of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-proBNP and Glomerular filtration rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood creatinine, blood urea nitrogen, indoxyl-sulfate, cardiac uhrasonography; | — |
Countries
China
Contacts
Shanghai Jiao Tong University School of Medicine